CARAMBA is a Horizon 2020 project investigating an innovative immunotherapy for the treatment of myeloma called Chimeric Antigen Receptor T-cell (CAR-T) therapy. CAR-T is a form of immunotherapy, which has demonstrated outstanding efficacy against various haematologic malignancies.
The CARAMBA clinical trial will take place in four centres of excellence in myeloma clinical care and research: University Hospital Würzburg (Germany), Ospedale San Raffaele (Italy), Universidad de Navarra (Spain) and the Centre Hospitalier Regional et Universitaire de Lille (France). Although each of the four clinical trial sites may begin enrolment at different times, the opening of the CARAMBA clinical trial was in August of 2020.
As part of the CARAMBA consortium, Myeloma Patients Europe (MPE) has developed an information sheet to explain the main goals and characteristics of this clinical trial, CAR-T side effects and consideration for patients and caregivers. This document will be translated into French, Italian, Spanish and German.
In the phase I/II CARAMBA clinical trial, T-cells are taken from patients and engineered to express a chimeric antigen receptor (CAR). This enables these T-cells to recognise the myeloma antigen (a protein commonly found on the surface of myeloma cells) SLAMF7. The T-cells can consequently find and destroy the myeloma cells.
This publication is the first one of a new MPE series of publications called “myeloma pipeline.” The “myeloma pipeline” publication series was created with the aim to provide patients with information about myeloma treatments currently being investigated in clinical trials.
The “myeloma pipeline” publication on CARAMBA can be accessed here.